Literature DB >> 20130960

Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.

Claudio Celeghini1, Rebecca Voltan, Erika Rimondi, Valter Gattei, Giorgio Zauli.   

Abstract

The effect of the single-chain alkylphospholipid perifosine was analyzed in p53(wild-type) (SKW6.4, OCI and MOLM), p53(mutated) (BJAB, MAVER) and p53(null) (HL-60) leukemic cell lines. Perifosine promoted cytotoxicity with a combination of apoptosis induction in all cell lines and cell cycle block at the G(2)M checkpoint, which was selectively observed in p53(mutated) BJAB and MAVER cell lines. At the molecular level, perifosine induced hypophosphorylation of retinoblastoma protein and the degradation of E2F1 protein in p53(mutated) but not in p53(wild-type) cells. These data indicate that perifosine potentially represents an innovative therapeutic approach for p53(mutated) hematological malignancies.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20130960     DOI： 10.1007/s10637-009-9370-1

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  9 in total

1.  TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells.

Authors:  P Secchiero; C Zerbinati; E Rimondi; F Corallini; D Milani; V Grill; G Forti; S Capitani; G Zauli
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

2.  Nuclear translocation of protein kinase C-alpha and -zeta isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid.

Authors:  G Zauli; G Visani; A Bassini; E Caramelli; E Ottaviani; L Bertolaso; V Bertagnolo; P Borgatti; S Capitani
Journal:  Br J Haematol       Date:  1996-06       Impact factor: 6.998

3.  Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy.

Authors:  Noriaki Mitani; Yoshimasa Niwa; Yasuyuki Okamoto
Journal:  Ann Clin Biochem       Date:  2007-11       Impact factor: 2.057

4.  Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways.

Authors:  Maria Nyåkern; Alessandra Cappellini; Irina Mantovani; Alberto M Martelli
Journal:  Mol Cancer Ther       Date:  2006-06       Impact factor: 6.261

Review 5.  Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects.

Authors:  Wim J van Blitterswijk; Marcel Verheij
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 6.  Emerging roles of E2Fs in cancer: an exit from cell cycle control.

Authors:  Hui-Zi Chen; Shih-Yin Tsai; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

7.  Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.

Authors:  Pier Luigi Tazzari; Giovanna Tabellini; Francesca Ricci; Veronica Papa; Roberta Bortul; Francesca Chiarini; Camilla Evangelisti; Giovanni Martinelli; Andrea Bontadini; Lucio Cocco; James A McCubrey; Alberto M Martelli
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

8.  Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.

Authors:  Paola Secchiero; Carlotta Zerbinati; Maria Grazia di Iasio; Elisabetta Melloni; Mario Tiribelli; Vittorio Grill; Giorgio Zauli
Journal:  Curr Drug Metab       Date:  2007-05       Impact factor: 3.731

9.  Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.

Authors:  Daniela Milani; Giorgio Zauli; Erika Rimondi; Claudio Celeghini; Sandra Marmiroli; Paola Narducci; Silvano Capitani; Paola Secchiero
Journal:  J Neurochem       Date:  2003-07       Impact factor: 5.372
  9 in total
  6 in total

1.  Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Authors:  Daniel C Cho; Thomas E Hutson; Wolfram Samlowski; Peter Sportelli; Brad Somer; Paul Richards; Jeffrey A Sosman; Igor Puzanov; M Dror Michaelson; Keith T Flaherty; Robert A Figlin; Nicholas J Vogelzang
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

2.  d-3-Deoxy-dioctanoylphosphatidylinositol induces cytotoxicity in human MCF-7 breast cancer cells via a mechanism that involves downregulation of the D-type cyclin-retinoblastoma pathway.

Authors:  Cheryl S Gradziel; Peter A Jordan; Delilah Jewel; Fay J Dufort; Scott J Miller; Thomas C Chiles; Mary F Roberts
Journal:  Biochim Biophys Acta       Date:  2016-09-04

3.  Reduced expression of the retinoblastoma protein shows that the related signaling pathway is essential for mediating the antineoplastic activity of erufosine.

Authors:  Maya M Zaharieva; Milen Kirilov; Minquang Chai; Stefan M Berger; Spiro Konstantinov; Martin R Berger
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

4.  LIM and SH3 protein 1 knockdown suppresses proliferation and metastasis of colorectal carcinoma cells via inhibition of the mitogen-activated protein kinase signaling pathway.

Authors:  Hongpeng Zhao; Bo Liu; Jie Li
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

5.  Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors.

Authors:  Erika Rimondi; Elisabetta Melloni; Arianna Romani; Veronica Tisato; Fabio Casciano; Gian Matteo Rigolin; Daniela Milani; Claudio Celeghini; Giorgio Zauli; Paola Secchiero; Rebecca Voltan
Journal:  Curr Oncol       Date:  2021-07-01       Impact factor: 3.677

6.  Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.

Authors:  Rebecca Voltan; Erika Rimondi; Elisabetta Melloni; Gian Matteo Rigolin; Fabio Casciano; Maria Vittoria Arcidiacono; Claudio Celeghini; Antonio Cuneo; Giorgio Zauli; Paola Secchiero
Journal:  Oncotarget       Date:  2016-10-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.